ACP

Leadership changes at the Accelerated Cure Project (ACP) for Multiple Sclerosis aim to enhance the nonprofit patient-founded organization’s research focus. Robert McBurney has stepped down as president and CEO after eight years to become ACP’s first chief research officer. He will continue in the position of research lead for the…

Hoping to expedite multiple sclerosis (MS) research and boost patient participation, the Accelerated Cure Project (ACP) for Multiple Sclerosis is teaming with the National Multiple Sclerosis Society. As part of the collaboration, the MS Society will make use of ACP’s iConquerMS, a research initiative to increase the engagement…

To increase the exchange of research information and goings-on with the patient community, the Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) has teamed with RealTalk MS, a weekly podcast for those affected by the disease. Specifically, ACP will share ongoing results of its research initiative, iConquerMS. In…

The Accelerated Cure Project (ACP) for Multiple Sclerosis and EMD Serono— a unit of Merck KGaA —  will jointly incorporate the perspectives of U.S. and Canadian multiple sclerosis (MS) patients into the design and implementation of clinical trials. The ACP, a nonprofit group based in Waltham, Massachusetts, strives to accelerate…

The Accelerated Cure Project for Multiple Sclerosis and a Regeneron unit are teaming up to sequence the coding portion of genes in DNA samples of multiple sclerosis and other patients in the project’s repository. The cure project is a non-profit organization whose goal is to accelerate research to improve MS diagnosis and…

BC Platforms announced that Biogen and the Accelerated Cure Project (ACP) will use its platform to advance research in multiple sclerosis (MS) by bringing data collected through clinical trials, biobanks and the like directly to researchers and other experts in the field. Microsoft is also a project partner,…